The option to continue or initiate treatment with approved AD medications during the trial, including cholinesterase inhibitors and recently approved anti-amyloid monoclonal antibody treatments that may be available during trial execution, will allow for important information to be gathered on the safety of concurrent use of these medications with different mechanisms of action and provides flexibility in an evolving therapeutic landscape
It may increase to 0.5 mg after four weeks
Researchers found that semaglutide use showed an increased risk of vision impairment compared to other GLP-1 RA medications
Rosenstock J, Balas B, Charbonnel B, Bolli GB, Boldrin M, Ratner R, et al
No worries try our Jennys Match Maker Free Online Consultation to see which stylist is right for you, your personality, and your hairstyle